SDIX is a renowned biotechnology company that specializes in creating enhanced antigens, antibodies, and assays for the pharmaceutical and biotechnology industries. With over 30 years of expertise, SDIX has become a leading provider of innovative antibody-based solutions to global customers, helping them achieve high-performance diagnostic and commercialization goals. As a wholly owned subsidiary of OriGene Technologies, SDIX focuses on high-quality, large-scale GMP antibody production in the United States, with facilities in Delaware and Maine.

All SDIX sites are ISO 13485:2016 certified, ensuring top-notch quality. SDIX offers a wide range of products and services, including IHC antibodies, IVD reagents, custom formulation and blending of IVD reagents, vendor management, contract manufacturing, and a newly expanded GMP vivarium facility. They also excel in cell line optimization, large-scale monoclonal antibody production (both in vivo and in vitro), cell banking and storage, and polyclonal bioprocessing.

With their commitment to quality and innovation, SDIX is your reliable partner in antibody development and production, contributing to a healthier tomorrow. Contact SDIX today to benefit from their cutting-edge solutions